Chimerix, Omthera Set Terms; IPO Lipidity Liquidity Ahead?
By Randy Osborne
Monday, April 1, 2013
Chimerix Inc. and Omthera Pharmaceuticals Inc. one with an antiviral based on lipid delivery, the other with a lipid-lowering therapy established terms for their initial public offerings (IPOs), raising investor hopes for a debut like that experienced last month by Enanta Pharmaceuticals Inc., but whether the fabled "window" will open for biotech firms this year remains in question.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.